Real-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer.
Future Oncol
; 19(26): 1785-1800, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-37665271
ABSTRACT
Aim:
Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer. We examined the real-world relationship between these end points in patients with resectable stage IB-IIIA non-small-cell lung cancer receiving neoadjuvant chemotherapy/chemoradiotherapy (CT/CRT).Methods:
Electronic health records/medical charts were analyzed. Overall and event-free survival (OS/EFS) were assessed by Kaplan-Meier stratified by pathologic response. Associations between the end points were assessed by Cox analyses.Results:
A total of 425 patients were selected for the study; 147 and 278 received CT and CRT, respectively. Pathologic complete response (pCR) was associated with longer OS (adjusted HR = 0.50; 95% CI 0.29-0.85) and EFS (adjusted HR = 0.44; 95% CI 0.28-0.68) versus no pCR, and EFS was associated with OS (HR = 0.51, 95% CI 0.38, 0.69).Conclusion:
In patients receiving neoadjuvant CT/CRT, pCR and EFS were associated with improved survival in this real-world dataset.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article